These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 15868958)
1. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP. Rennicke A; Voigt W; Mueller T; Fruehauf A; Schmoll HJ; Beyer C; Dempke W Anticancer Res; 2005; 25(2A):1147-55. PubMed ID: 15868958 [TBL] [Abstract][Full Text] [Related]
2. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins. Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548 [TBL] [Abstract][Full Text] [Related]
3. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864 [TBL] [Abstract][Full Text] [Related]
4. The role of DNA mismatch repair in platinum drug resistance. Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738 [TBL] [Abstract][Full Text] [Related]
5. In vitro studies on the mechanisms of oxaliplatin resistance. Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458 [TBL] [Abstract][Full Text] [Related]
6. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Nehmé A; Baskaran R; Nebel S; Fink D; Howell SB; Wang JY; Christen RD Br J Cancer; 1999 Mar; 79(7-8):1104-10. PubMed ID: 10098743 [TBL] [Abstract][Full Text] [Related]
8. Sequential X-irradiation induced acquired resistance to oxaliplatin but increased sensitivity to cisplatin in two human teratoma cell lines in vitro. Eisenmann S; Voigt W; Müller T; Dempke W Anticancer Res; 2010 Nov; 30(11):4471-6. PubMed ID: 21115895 [TBL] [Abstract][Full Text] [Related]
9. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines. Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053 [TBL] [Abstract][Full Text] [Related]
10. The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells. Perego P; Gatti L; Caserini C; Supino R; Colangelo D; Leone R; Spinelli S; Farrell N; Zunino F J Inorg Biochem; 1999 Oct; 77(1-2):59-64. PubMed ID: 10626355 [TBL] [Abstract][Full Text] [Related]
11. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination. Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450 [TBL] [Abstract][Full Text] [Related]
12. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer. Wang S; Zhang H; Scharadin TM; Zimmermann M; Hu B; Pan AW; Vinall R; Lin TY; Cimino G; Chain P; Vuyisich M; Gleasner C; Mcmurry K; Malfatti M; Turteltaub K; de Vere White R; Pan CX; Henderson PT PLoS One; 2016; 11(1):e0146256. PubMed ID: 26799320 [TBL] [Abstract][Full Text] [Related]
13. One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes. Yamada K; Kato N; Takagi A; Koi M; Hemmi H Anal Bioanal Chem; 2005 Aug; 382(7):1702-7. PubMed ID: 15959768 [TBL] [Abstract][Full Text] [Related]
14. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10. Hector S; Nava ME; Clark K; Murphy M; Pendyala L Cancer Lett; 2007 Jan; 245(1-2):195-204. PubMed ID: 16516375 [TBL] [Abstract][Full Text] [Related]
15. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Branch P; Masson M; Aquilina G; Bignami M; Karran P Oncogene; 2000 Jun; 19(28):3138-45. PubMed ID: 10918568 [TBL] [Abstract][Full Text] [Related]
16. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Fink D; Nebel S; Norris PS; Baergen RN; Wilczynski SP; Costa MJ; Haas M; Cannistra SA; Howell SB Int J Cancer; 1998 Aug; 77(5):741-6. PubMed ID: 9688308 [TBL] [Abstract][Full Text] [Related]
17. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810 [TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380 [TBL] [Abstract][Full Text] [Related]
19. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Aebi S; Fink D; Gordon R; Kim HK; Zheng H; Fink JL; Howell SB Clin Cancer Res; 1997 Oct; 3(10):1763-7. PubMed ID: 9815561 [TBL] [Abstract][Full Text] [Related]
20. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells. O'Neill CF; Hunakova L; Kelland LR Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]